Education
About Us
Working with TipRanks
Follow Us
Gemina Laboratories Ltd. (TSE:GLAB)
:GLAB
GLAB Stock Chart & Stats
C$0.06
-C$0.02(-2.86%)
At close: 4:00 PM EST
C$0.06
-C$0.02(-2.86%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$1.25
Previous CloseN/A
Volume500.00
Average Volume (3M)13.56K
Market Cap
C$2.30M
Enterprise ValueC$4.83M
Total Cash (Recent Filing)-C$613.00
Total Debt (Recent Filing)C$240.11K
Price to Earnings (P/E)―
Beta-0.97
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,570,910
10 Day Avg. Volume19,305
30 Day Avg. Volume13,558
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-9.02
Price to Sales (P/S)0.00
P/FCF Ratio-30.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Operating Cash Flow ImprovementA shift from multi-year cash burn to slightly positive TTM operating and free cash flow signals an early improvement in cash dynamics. If sustained, even modest positive cash generation reduces reliance on immediate financing and provides management optionality to prioritize key R&D or milestone spending over short-term survival actions.
Low Absolute DebtModest absolute debt levels relative to assets limit near-term fixed financing obligations and interest burden. For a small biotech with accumulated deficits, low external debt preserves flexibility to raise equity or strike partnerships without immediate pressure from creditors, supporting runway extension for development programs.
Lean Operating FootprintA very small headcount implies a lean cost base, which can materially extend runway and reduce cash burn in early-stage biotech. Lower fixed payroll and overhead allow management to direct limited resources toward critical experiments or regulatory milestones, preserving capital while seeking value-accretive partnerships or financing.
Bears Say
Minimal Revenue GenerationNear-zero product or commercial revenue demonstrates the company remains pre-commercial and unproven at scale. Without recurring revenue, long-term sustainability depends on successful R&D outcomes or continual external financing, increasing dilution and execution risk versus firms with established sales or licensing cash flows.
Large Losses And Negative Gross ProfitSubstantial cumulative losses and a negative equity position indicate capital erosion from operations. Negative gross profit and a multi-million net loss constrain strategic choices, reduce creditor confidence, and make financing terms harder, elevating insolvency risk if R&D fails to produce near-term milestones or partner support.
Fragile Cash GenerationThe TTM cash flow improvement is extremely small and not yet supported by sustained revenue or operating leverage. This fragility means any adverse expense shock or delayed milestone could quickly reverse cash gains, forcing rapid capital raises under unfavorable terms and threatening long-term program continuity.
Gemina Laboratories Ltd. News
GLAB FAQ
What was Gemina Laboratories Ltd.’s price range in the past 12 months?
Gemina Laboratories Ltd. lowest stock price was C$0.03 and its highest was C$1.25 in the past 12 months.
What is Gemina Laboratories Ltd.’s market cap?
Gemina Laboratories Ltd.’s market cap is C$2.30M.
When is Gemina Laboratories Ltd.’s upcoming earnings report date?
Gemina Laboratories Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 100 days.
How were Gemina Laboratories Ltd.’s earnings last quarter?
Gemina Laboratories Ltd. released its earnings results on Dec 30, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Gemina Laboratories Ltd. overvalued?
According to Wall Street analysts Gemina Laboratories Ltd.’s price is currently Overvalued.
Does Gemina Laboratories Ltd. pay dividends?
Gemina Laboratories Ltd. does not currently pay dividends.
What is Gemina Laboratories Ltd.’s EPS estimate?
Gemina Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Gemina Laboratories Ltd. have?
Gemina Laboratories Ltd. has 76,570,910 shares outstanding.
What happened to Gemina Laboratories Ltd.’s price movement after its last earnings report?
Gemina Laboratories Ltd. reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -40%.
Which hedge fund is a major shareholder of Gemina Laboratories Ltd.?
Currently, no hedge funds are holding shares in TSE:GLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gemina Laboratories Ltd.
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Technical Analysis
Restart Life Sciences
―
Entheon Biomedical
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Doseology Sciences
―